Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trial
Official title:
Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases
Chronic inflammatory demyelinating polyradiculoneuritis (CIDP) is an autoimmune disorder of the peripheral nervous system, most commonly affecting the myelin sheath. The pathophysiology of CIDP is not completely understood, but both humoral and cellular immunity appear to be involved in the genesis of this disease. Some diseases are particularly associated with CIDP such as diabetes, monoclonal gammopathies and hematological diseases. CIDP can occur before, after or simultaneously with the onset of systemic diseases. The systemic diseases most often seen in association with polyneuropathies are lupus, Gougerot-Sjögren's syndrome and sarcoidosis. Ultrasound of peripheral nerves is a useful and accessible tool. In CIDP, this examination can reveal diffuse or segmental nerve hypertrophy. In addition to the size of the nerve, this exploration analyzes the echogenicity and the aspect of the different fascicles within the nerve. S. Goedee et al have shown that nerve ultrasound has very good diagnostic parameters and low interobserver variability in the diagnosis of CIDP. F. Härtig et al suggests that nerve ultrasound can predict the therapeutic response and describes 3 main patterns: hypoechoic enlargement (active inflammation), nerve enlargement with hyperechoic add-on fascicles (axonal degeneration) and almost no enlargement ("cured" CIDP).
CIDP may be progressive or relapsing, most frequently clinically symmetric, sensorimotor with proximal and distal involvement developing over at least 8 weeks but variants as distal, multifocal, focal, motor or sensory CIDP have been also described. Cell-mediated and humoral mechanisms act together in an aberrant immune response to cause damage to peripheral nerves but, by molecular mimicry it causes other autoimmune system diseases. This paper focuses on the intersection of CIDP and other autoimmune disease with an emphasis on shared pathology and mutually characteristics. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04356781 -
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
|
||
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Terminated |
NCT01225276 -
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
|
Phase 2/Phase 3 | |
Completed |
NCT02892890 -
Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
|
N/A | |
Active, not recruiting |
NCT03584022 -
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
|
N/A | |
Terminated |
NCT02317562 -
Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
|
Phase 3 | |
Recruiting |
NCT06325878 -
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
N/A | |
Recruiting |
NCT06290128 -
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
|
Phase 3 | |
Completed |
NCT02293460 -
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
|
Phase 3 | |
Completed |
NCT02017769 -
MRI in Diagnosing and Monitoring CIDP
|
N/A | |
Completed |
NCT03967899 -
Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
||
Not yet recruiting |
NCT04978623 -
Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
|
||
Active, not recruiting |
NCT02404298 -
Transcriptome Analysis of the Peripheral Blood in CIDP
|
N/A | |
Completed |
NCT00099489 -
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Phase 2 | |
Completed |
NCT01625182 -
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
|
Phase 3 | |
Completed |
NCT02549170 -
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Phase 3 | |
Completed |
NCT02955355 -
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
|
Phase 3 | |
Active, not recruiting |
NCT04658472 -
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 2 | |
Withdrawn |
NCT04529291 -
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
N/A |